Monte Rosa Therapeutics Inc. highlighted progress in its pipeline of molecular glue degraders (MGDs), with three clinical programs advancing toward Phase 2 trials anticipated in 2026. The company is targeting highly validated proteins implicated in diseases with significant unmet medical needs, leveraging its AI-driven QuEEN platform for rational design and selectivity. Recent collaborations include a partnership with Novartis to accelerate development of degraders for immune-mediated diseases, featuring an upfront payment of $120 million and potential deal value up to $5.7 billion. Another agreement with Roche focuses on cancer and neurological disease targets, with Monte Rosa leading early-stage activities. The company anticipates additional investigational new drug applications for its pipeline over the next two years. You can access the full presentation through the link below.